Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,184 recruiting studies in this area right now.
By phase
- Not applicable2,936
- Phase 2755
- Phase 1540
- Phase 3382
- Phase 1/Phase 2297
- Phase 4211
- Phase 2/Phase 363
Top conditions
- Breast Cancer1,226
- Melanoma183
- Rheumatoid Arthritis142
- Metastatic Breast Cancer140
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Breast Neoplasms120
- Triple Negative Breast Cancer117
- Colorectal Cancer93
- Ovarian Cancer92
- Psoriasis88
- Breast Carcinoma83
- Lung Cancer79
- Prostate Cancer70
- Rheumatoid Arthritis (RA)65
- Diabetic Foot Ulcer61
- Systemic Sclerosis60
- Cancer58
Leading sponsors
- Fudan University66
- M.D. Anderson Cancer Center52
- Memorial Sloan Kettering Cancer Center50
- Novartis Pharmaceuticals47
- Mayo Clinic42
- Assistance Publique - Hôpitaux de Paris41
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37
- AstraZeneca36
- National Cancer Institute (NCI)35
- Second Affiliated Hospital, School of Medicine, Zhejiang University30
Where studies are running
- California421
- Arizona159
- Florida131
- Alabama127
- New York109
- Texas107
- Massachusetts93
- Maryland91
- Pennsylvania75
- North Carolina68
Recruiting studies5,184 total
- NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85 - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT05756179RecruitingPhase 3
Diosmin and hesperidin for mild to moderate rheumatoid arthritis
This trial tests whether two natural plant-based medicines (diosmin and hesperidin) can reduce symptoms in people with mild to moderate rheumatoid arthritis. It compares treatment outcomes to standard care to see if these supplements help control the disease.
AlexandriaAges 19–65 - NCT05758532RecruitingPhase 4
Modified measles vaccine schedule to help prevent allergies in babies
This study tests whether changing the measles vaccine timing in 6-month-old children can reduce allergy risk and also help protect against unrelated infections. If your child is already up to date with routine vaccines, they may be eligible for a modified measles (MMR) schedule used in the trial.
GenevaAges 6 months–6 months - NCT05758545Recruiting
Device treatment for diabetic foot ulcers with poor blood flow
This trial tests whether COMS One is safe and effective for healing a specific diabetic foot ulcer. It may help people whose ulcer is not healing well, especially when blood flow to the foot is limited.
Mesa, ArizonaAges 22–90 - NCT05759780Recruiting
Check how an eye probe measures tissue softness
This study uses a special eye/skin/gum imaging test to measure how tissues behave. It may help researchers improve noninvasive ways to understand eye and tissue health, and in some parts of the study, mild keratoconus.
Boston, MassachusettsAges 18–75 - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05760898Recruiting
Helping control blood pressure in people with rheumatoid arthritis
This study aims to improve blood pressure control in adults who have both uncontrolled high blood pressure and rheumatoid arthritis. It may help by testing ways to better coordinate care between primary care and rheumatology.
Durham, North CarolinaAges 18 years+ - NCT05761314Recruiting
Study treatments for cancers in people with RASopathy
This study looks at people who have a RASopathy—a genetic condition—and also have solid tumors (tumor growths not in blood). To join, your RASopathy must be confirmed by genetic testing, not only by symptoms.
RomaAges Any age - NCT05762432Recruiting
Wound dressing study for certain diabetic foot ulcers
This study looks at a specific wound dressing in people with a non-infected diabetic foot ulcer that has nerve pain (neuropathic), poor blood flow (ischemic), or both. It may help you heal the ulcer and improve how the wound looks and progresses.
Airdrie, North LanarkshireAges 18 years+ - NCT05762900RecruitingPhase 2
Shorter breast radiation after surgery for low-risk breast cancer
This Phase 2 trial tests a shorter, focused radiation treatment after breast surgery, either alone or with an extra targeted boost. It’s for people with low-risk breast cancer and no spread to distant organs, aiming to keep results while reducing treatment time and side effects.
BeijingAges 35 years+ - NCT05763641Recruiting
Targeted treatment after chemo for certain breast cancers
This trial studies an additional treatment given after chemotherapy for locally advanced breast cancer that has spread to specific underarm lymph nodes. It may help some people reduce cancer returning, especially when tumors match certain growth and spread features.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT05766410RecruitingPhase 2
Testing three CDK4/6 pills to change the immune response
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
TaipeiAges 20 years+ - NCT05767047RecruitingPhase 3
Apremilast study for children with mouth ulcers from Behçet’s
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
ThessalonikiAges 5–18 - NCT05766891RecruitingPhase 2/Phase 3
Nurse-led hypnosis to reduce opioid pain meds for breast surgery
This trial tests whether nurse-delivered hypnosis during breast cancer surgery can help you need less opioid pain medicine after surgery. It may make recovery more comfortable while aiming to lower opioid use.
Houston, TexasAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05772390RecruitingPhase 2
Second radiation for a small breast cancer return
This Phase 2 study tests whether giving targeted radiation again to the same breast can control a small, local breast cancer that came back after prior whole-breast radiation. It may help some patients avoid or delay further treatment for the breast while carefully checking safety.
Meldola, Forlì CesenaAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,184 recruiting dermatology studies from the U.S. registry right now, out of 8,288 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.